PCT

(22) International Filing Date:





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:
C12N 15/31, C07K 14/37, C12Q 1/04

(21) International Application Number:

C21N 15/31, C07K 14/37, C12Q 1/04

(21) International Application Number:

C31N 15/31, C07K 14/37, C12Q 1/04

(21) International Application Number:

C31N 15/31, C07K 14/37, C12Q 1/04

(21) International Application Number:

C31N 15/31, C07K 14/37, C12Q 1/04

(21) International Application Number:

C31N 15/31, C07K 14/37, C12Q 1/04

(22) International Application Number:

C31N 15/31, C07K 14/37, C12Q 1/04

(23) International Publication Date:

C43N 15/31, C07K 14/37, C12Q 1/04

(24) International Application Number:

C43N 15/31, C07K 14/37, C12Q 1/04

(25) International Application Number:

C5N 15/31, C07K 14/37, C12Q 1/04

23 March 2000 (23.03.00)

60/125,717 23 March 1999 (23.03.99) US

(71) Applicant (for all designated States except US): CYTO-CLONAL PHARMACEUTICS, INC. [US/US]; 9000 Harry Hines Boulevard, Dallas, TX 75235 (US).

(72) Inventors; and

(30) Priority Data:

(75) Inventors/Applicants (for US only): SIDHU, Rajinder, S. [US/US]; 7521 Danfield Court, Dallas, TX 75252 (US). BOLLON, Arthur, P. [US/US]; 13227 Cedar Lane, Dallas, TX 75234 (US). MU, Jing-Hong [CN/US]; 534 Newberry Drive, Richardson, TX 75080 (US).

(74) Agents: HANSEN, Eugenia, S. et al.; Sidley & Austin, Suite 3400, 717 N. Harwood, Dallas, TX 75201 (US).

I) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time lim

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: FUNGAL BETA-TUBULIN GENES

(57) Abstract

The same

The anticancer drug taxol binds to beta-tubulin in assembled microtubules (MT) and causes cell cycle arrest in animal cells; in contrast, the effect of taxol varies in fungi. For instance, the taxol-producer Pestalotiopsis microspora Ne32, an ascomycete, is resistant to taxol (1C50>11.7 M), whereas Pythium ultimum and Phytophthora cinnamomi, two oomycetes, are sensitive to taxol (1C50 0.1 μ M). cDNAs encoding beta-tubulin from P.microspora, P. ultimum, and P. cinnamomi were isolated. The deduced amino acid sequences of beta-tubulin from P. microspora, P.ultimum, and P. cinnamomi can be used in (1) binding assays for the detection of taxol and taxol-like substances; (2) diagnostic assays for the pharmacologic efficacy of taxol against a tumor sample; (3) designing drugs with taxol-like activity via application of information regarding the effect of specific residues on taxol binding; and (4) detection of taxol and taxol-like activity via use of taxol-sensitive and taxol-resistant isogenic strains of P.ultimum constructed by substitution of residues necessary for taxol binding.